Description:
Study CPX351-103 is an open-label, multicenter, phase 1b, safety and PK study to determine
the MTD of the combination of CPX 351 and venetoclax when administered to subjects with newly
diagnosed AML who are unfit for intensive chemotherapy (ICT). This study will comprise 2
phases: a Dose Escalation Phase and an Expansion Phase, in which all subjects will receive a
combination of CPX-351 and venetoclax.
Title
- Brief Title: A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML
- Official Title: A Phase 1b Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML Who Are Unfit for Intensive Chemotherapy
Clinical Trial IDs
- ORG STUDY ID:
CPX351-103
- NCT ID:
NCT04038437
Conditions
Interventions
Drug | Synonyms | Arms |
---|
CPX-351 | Vyxeos | CPX-351 and Venetoclax |
Venetoclax | Venclexta | CPX-351 and Venetoclax |
Purpose
Study CPX351-103 is an open-label, multicenter, phase 1b, safety and PK study to determine
the MTD of the combination of CPX 351 and venetoclax when administered to subjects with newly
diagnosed AML who are unfit for intensive chemotherapy (ICT). This study will comprise 2
phases: a Dose Escalation Phase and an Expansion Phase, in which all subjects will receive a
combination of CPX-351 and venetoclax.
Trial Arms
Name | Type | Description | Interventions |
---|
CPX-351 and Venetoclax | Experimental | CPX-351 and Venetoclax will be administered over 28 day cycles | |
Eligibility Criteria
Inclusion Criteria:
• Subject must have newly diagnosed AML with histological confirmation by World Health
Organization (WHO) criteria.
Definition of subjects who are unfit for ICT:
• Each subject must meet the following criteria characterizing him / her as unfit to
receive ICT within 21 days prior to the first day of therapy to be enrolled in the study:
- ≥ 75 years of age OR
- ≥ 18 to 74 years of age and fulfilling at least 1 criteria associated with lack of
fitness for ICT as follows:
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 to 3;
- Cardiac history of Congestive Heart Failure (CHF) requiring treatment or left
ventricular ejection fraction (LVEF) ≤ 50%.
- Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) ≤ 65% or Forced
Expiratory Volume in 1 second (FEV1) ≤ 65%;
- Creatinine clearance (CrCl) ≥ 30 mL/min to < 45 mL/min calculated by the
Cockcroft-Gault formula;
- Moderate hepatic impairment with total bilirubin > 1.5 to ≤ 3.0 × Upper Limit of
Normal (ULN);
- Other comorbidity that the physician judges to be incompatible with conventional
intensive chemotherapy which must be reviewed and approved by the study medical
monitor before study enrollment.
In addition, all subjects must meet the following criteria:
- If the subject is ≥ 75 years of age, then ECOG Performance Status must be 0-2.
- Subject must have adequate renal function as demonstrated by a CrCl ≥ 30 mL/min
(calculated by the Cockcroft Gault formula or measured by 24-hour urine collection).
- Subject must have adequate liver function as demonstrated by:
- Aspartate aminotransferase (AST) ≤ 3.0 × ULN*
- Alanine aminotransferase (ALT) ≤ 3.0 × ULN*
- Bilirubin ≤ 1.5 × ULN (subjects who are < 75 years of age may have bilirubin of ≤
3.0 × ULN)* *Unless considered to be due to leukemic organ involvement.
- Female subjects must be either postmenopausal defined as:
- Age > 55 years with no menses for ≥ 2 years without an alternative medical cause.
- OR
- Age ≤ 55 years with no menses for ≥ 12 months without an alternative medical
cause AND a follicle-stimulating hormone level > 40 IU/L;
- OR
- Permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or
hysterectomy); OR
- A woman of childbearing potential practicing at least 1 protocol specified method of
birth control starting at Study Day 1 through at least 6 months after the last dose of
study treatment.
- A woman of childbearing potential must have negative results for pregnancy test
performed:
- At Pretreatment with a serum sample obtained within 14 days prior to the first
study treatment administration, and
- Prior to dosing with urine sample obtained on Cycle 1 Day 1, if it has been > 7
days since obtaining the serum pregnancy test results.
- Subjects with borderline pregnancy tests at Pretreatment must have a serum
pregnancy test ≥ 3 days later to document continued lack of a positive result.
- Male subjects who are sexually active, must agree, from Study Day 1 through at least 6
months after the last dose of study treatment, to practice protocol specified methods
of contraception. Male subjects must agree to refrain from sperm donation from initial
study treatment administration through at least 6 months after the last dose of study
treatment.
- Subject must have a white blood cell count ≤ 25 × 109/L. (Note: subjects who have
undergone hydroxyurea administration or leukapheresis for therapeutic cytoreduction
will be considered eligible).
Exclusion Criteria:
- Subject has ECOG Performance Status > 3, regardless of age.
- Subject has known Human Immunodeficiency Virus (HIV) infection (due to potential
drug-drug interactions between antiretroviral medications and venetoclax). HIV testing
will be performed at Pretreatment, if required per local guidelines or institutional
standards.
- Subject has consumed grapefruit, grapefruit products, Seville oranges (including
marmalade containing Seville oranges) or Star fruit within 3 days prior to the
initiation of study treatment.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Maximum Tolerated Dose (MTD) as determined by the specified dose escalation |
Time Frame: | Up to 30 months |
Safety Issue: | |
Description: | The MTD as determined by the specified dose escalation and MTD algorithm |
Secondary Outcome Measures
Measure: | Proportion of subjects who have achieved CR, CRi, PR, and CRc (CR + CRi) |
Time Frame: | Up to 30 months |
Safety Issue: | |
Description: | Proportion of subjects who have achieved CR, CRi, PR, and CRc (CR + CRi) by the completion of treatment (up to 4 cycles of therapy) |
Measure: | Proportion of subjects who have achieved ORR |
Time Frame: | Up to 30 months |
Safety Issue: | |
Description: | Proportion of subjects who have achieved ORR, defined as best response (CR + CRi + PR) by the completion of treatment (up to 4 cycles of therapy) |
Measure: | Proportion of subjects who have achieved CR / CRi with MRD status |
Time Frame: | Up to 30 months |
Safety Issue: | |
Description: | Proportion of subjects who have achieved CR / CRi with MRD status (negative / positive) by the completion of treatment (up to 4 cycles of therapy) |
Measure: | AUCtau |
Time Frame: | Up to 30 months |
Safety Issue: | |
Description: | Area under the plasma concentration time curve from time 0 to the time of the next dosing during a 48 hour interval at the steady-state of CPX-351 PK |
Measure: | Maximum Plasma Concentration (Cmax) |
Time Frame: | Up to 30 months |
Safety Issue: | |
Description: | |
Measure: | Time to Cmax (Tmax) |
Time Frame: | Up to 30 months |
Safety Issue: | |
Description: | |
Measure: | Apparent Terminal Elimination Half-Life (t½) |
Time Frame: | Up to 30 months |
Safety Issue: | |
Description: | |
Details
Phase: | Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Jazz Pharmaceuticals |
Trial Keywords
- CPX-351
- Vyxeos
- Venetoclax
- Unfit
Last Updated
August 27, 2021